Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pfister

Showing results (351-360 of 380) with videos related to

Pageof 38
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[Treatment of infiltrating nonmetastatic bladder cancers in elderly patients]H Quintens, L Guy, C Mazerolles, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 12, 2010
[T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)]B Faivre d'Arcier, O Celhay, A Safsaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2024
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trialC S Groeneveld, C Pfister, S Culine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 7, 2010
[Recommendations Onco-Urology 2010: Urothelial tumors]C Pfister, M Roupret, H Wallerand, et al.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[Incidence and mortality of urological cancers in 2012 in France]X Rébillard, P Grosclaude, N Leone, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]E Compérat, S Larré, Y Neuzillet, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Bladder carcinoma]C Pfister, M Roupret, Y Neuzillet, et al.
Pageof 38

Showing results (351-360 of 380) with videos related to

Sort By:
Pageof 38
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[Treatment of infiltrating nonmetastatic bladder cancers in elderly patients]H Quintens, L Guy, C Mazerolles, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 12, 2010
[T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)]B Faivre d'Arcier, O Celhay, A Safsaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2024
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trialC S Groeneveld, C Pfister, S Culine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 7, 2010
[Recommendations Onco-Urology 2010: Urothelial tumors]C Pfister, M Roupret, H Wallerand, et al.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[Incidence and mortality of urological cancers in 2012 in France]X Rébillard, P Grosclaude, N Leone, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]E Compérat, S Larré, Y Neuzillet, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2014
[CCAFU Recommendations 2013: Bladder carcinoma]C Pfister, M Roupret, Y Neuzillet, et al.
Pageof 38